Archive

Mylan options trading rises on takeover speculation, court ruling | TribLIVE.com
News

Mylan options trading rises on takeover speculation, court ruling

Bullish Mylan Inc. options trading rose to the highest since July 2009 on speculation that the biggest U.S. maker of generic drugs may be acquired and after a U.K. judge ruled that rival Cephalon Inc. can’t prevent it from selling a sleep-disorder treatment.

Almost 40,000 calls to buy the stock changed hands, 13 times average and eight times the number of puts to sell on Friday. Mylan shares rose 3.1 percent to $19.85.

The options trading was spurred by “unsubstantiated takeover rumors,” strategists at Susquehanna International Group LLP in Bala Cynwyd, Pa., wrote in a note to clients. Michael Laffin, a spokesman for Canonsburg-based Mylan, didn’t return a call for comment.

Cephalon, maker of the sleep-disorder drug Provigil, can’t stop Mylan and Orchid Chemicals & Pharmaceuticals Ltd. from selling generic versions of the medicine in Britain before a patent trial, the High Court in London ruled.


TribLIVE commenting policy

You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.